GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Flexion Therapeutics Inc (NAS:FLXN) » Definitions » EBIT per Share

Flexion Therapeutics (Flexion Therapeutics) EBIT per Share : $-1.59 (TTM As of Sep. 2021)


View and export this data going back to 2014. Start your Free Trial

What is Flexion Therapeutics EBIT per Share?

Flexion Therapeutics's EBIT per Share for the three months ended in Sep. 2021 was $-0.49. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2021 was $-1.59.

During the past 3 years, the average EBIT per Share Growth Rate was 19.30% per year. During the past 5 years, the average EBIT per Share Growth Rate was -1.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Flexion Therapeutics's EBIT per Share or its related term are showing as below:

FLXN' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -31.8   Med: -18.8   Max: 19.3
Current: 19.3

During the past 10 years, the highest 3-Year average EBIT per Share Growth Rate of Flexion Therapeutics was 19.30% per year. The lowest was -31.80% per year. And the median was -18.80% per year.

FLXN's 3-Year EBIT Growth Rate is not ranked
in the Drug Manufacturers industry.
Industry Median: 7.95 vs FLXN: 19.30

Flexion Therapeutics's EBIT for the three months ended in Sep. 2021 was $-24.5 Mil.


Flexion Therapeutics EBIT per Share Historical Data

The historical data trend for Flexion Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Flexion Therapeutics EBIT per Share Chart

Flexion Therapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
EBIT per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.77 -3.82 -4.08 -3.48 -2.07

Flexion Therapeutics Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.39 -0.29 -0.47 -0.34 -0.49

Flexion Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Flexion Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2020 is calculated as

EBIT per Share(A: Dec. 2020 )
=EBIT/Shares Outstanding (Diluted Average)
=-93.184/45.013
=-2.07

Flexion Therapeutics's EBIT per Share for the quarter that ended in Sep. 2021 is calculated as

EBIT per Share(Q: Sep. 2021 )
=EBIT/Shares Outstanding (Diluted Average)
=-24.525/50.265
=-0.49

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Flexion Therapeutics  (NAS:FLXN) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.


Flexion Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Flexion Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Flexion Therapeutics (Flexion Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
10 Mall Road, Suite 301, Burlington, MA, USA, 01803
Flexion Therapeutics Inc is a United States-based specialty pharmaceutical company. The company focuses on the development and commercialization of novel, local therapies. The company specializes in the treatment of patients with musculoskeletal conditions beginning with osteoarthritis. The products offered by company are zilretta which is used for enhancing the clinical effect of intra-articular corticosteroid treatment.
Executives
Mark S. Levine officer: General Counsel 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
Kerry Wentworth officer: Chief Regulatory Officer AGENUS INC., 3 FORBES ROAD, LEXINGTON MA 02421
Christina Willwerth officer: Chief Strategy Officer C/O FLEXION THERAPEUTICS, INC. 10 MALL ROAD, SUITE 301 BURLINGTON MA 01803
David Arkowitz officer: Chief Financial Officer C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Melissa Layman officer: Chief Commercial Officer C/O FLEXION THERAPEUTICS, INC. 10 MALL ROAD, STE. 301 BURLINGTON MA 01803
Scott Kelley officer: Chief Medical Officer C/O ASPECT MEDICAL SYSTEMS INC 141 NEEDHAM ST NEWTON MA 02464-1505
Elizabeth Kwo director C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Michael D. Clayman director, officer: President and CEO C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Alan Milinazzo director C/O ORTHOFIX INC, 10115 KINCEY AVENUE STE 250, HUNTERSVILLE NC 28078
Scott A Canute director FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
C Ann Merrifield director
Heath Lukatch director 326 BOLLAY DRIVE, GOLETA CA 93117
Samuel D Colella director, 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Patrick J Mahaffy director C/O CLOVIS ONCOLOGY, INC., 5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80301
Mark Stejbach director C/O TENGION, INC., 2900 POTSHOP LANE, SUITE 100, EAST NORRITON PA 19403